CN110314183A - A kind of composition and the preparation method and application thereof for alleviating hyperthyroidism - Google Patents
A kind of composition and the preparation method and application thereof for alleviating hyperthyroidism Download PDFInfo
- Publication number
- CN110314183A CN110314183A CN201810298854.0A CN201810298854A CN110314183A CN 110314183 A CN110314183 A CN 110314183A CN 201810298854 A CN201810298854 A CN 201810298854A CN 110314183 A CN110314183 A CN 110314183A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- preparation
- thyroid
- hyperthyroidism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 206010020850 Hyperthyroidism Diseases 0.000 title claims abstract description 19
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 35
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 35
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000036541 health Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 241000212941 Glehnia Species 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000170916 Paeonia officinalis Species 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 abstract description 45
- 230000000694 effects Effects 0.000 abstract description 20
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 4
- 239000005495 thyroid hormone Substances 0.000 abstract description 4
- 229940036555 thyroid hormone Drugs 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 17
- 239000002994 raw material Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 240000005001 Paeonia suffruticosa Species 0.000 description 9
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 241000736199 Paeonia Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940034208 thyroxine Drugs 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 102000015486 thyroid-stimulating hormone receptor activity proteins Human genes 0.000 description 2
- 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 2
- 230000001646 thyrotropic effect Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 244000146486 Glehnia littoralis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010063885 Radiation thyroiditis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000002015 Thyroid Crisis Diseases 0.000 description 1
- 206010043786 Thyrotoxic crisis Diseases 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940036571 iodine therapy Drugs 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- -1 oral solution Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to health product technology fields, disclose a kind of composition and the preparation method and application thereof for alleviating hyperthyroidism.Composition of the present invention, by weight, by 2-30 parts of cape jasmine, 2-30 parts of Radix Paeoniae Alba, 2-30 parts and cortex moutan 2-30 parts of Radix Glehniae are made.Composition of the present invention is made of cape jasmine, Radix Paeoniae Alba, Radix Glehniae and cortex moutan, and each component reasonable compatibility generates synergy synergistic effect.Experiment shows, composition of the present invention can improve the thyroid function of the hyperfunction model mice of thyroid gland, inhibit the proliferation of thyroid cell, improve thyroid hormone FT3, FT4 and TSH level, alleviate Thyroid Gland Swell symptom, to play the role of alleviating hyperthyroidism.The composition is simple, highly-safe, has no toxic side effect, quickly effective, and curative effect is clear.
Description
Technical field
The invention belongs to technical field of health care food, and in particular to a kind of for alleviating the composition of hyperthyroidism
And the preparation method and application thereof.
Background technique
Graves disease (Graves ' disease, GD), i.e. graves disease, are a kind of autoimmunity diseases, are
Hyperthyroidism one of the most common type type.In recent years, it lives with Factors on Human such as diet, feelings will, environment
It influences, GD illness trend increases year by year, and women is significantly higher than male.Clinically it is mainly shown as Thyroid Gland Swell, basic generation
It thanks to rate and nerve excitability increases, if palpitaition, hidrosis, dysphoria with smothery sensation, damp sweat, pulse are fast, hand tremor, more foods, thin, out of strength and expophthalmos
Deng.
GD patient's body contains thyrotropin receptor antibody (TRAb), the immune function of the TRAb prompt GD patient occurred extremely
It can get muddled.After TRAb and thyrotropin receptor (TSHR) are combined, the function of similar thyrotropic hormone (TSH) can be played
Can, it stimulates thyroid cell hyperplasia and generates excessive thyroxine (Thyroxine, T4) and triiodo thryonine (T3),
Patient is set hypermetabolism symptom and thyroid gland anthorisma occur.The feature sex expression of goitre wonderful works GD is because of first
Caused by the enlargement or proliferation of shape gland cell, it is related that this may die mechanism to the proliferation of thyroid cell and tune.
Currently, common treatment method has: antithyroidin drug (ATD) treatment,131I treatment and operative treatment.Operation
It treats in being commonly used in, severe hyperthyroidism, has the function that inhibit the state of an illness by cutting off Thyroid Lesion, to the doctor of doctor
Art is more demanding, quick, but complication is relatively more.It cuts and has lacked the meeting recurrent exerbation exacerbation state of an illness, having cut more then may cause forever
Long property first subtracts, hypoparathyroidism, recurrent nerve injury, bleeding infection and thyroid crisis etc..131I treatment is also known as put
Penetrating property iodine therapy.131The β ray that I is released has damage effect to thyroid gland, simultaneously131I can be absorbed by thyroid gland height, make first
Shape galandular epithelium folliculus destroys and reduces the secretion of thyroid hormone, while lymphocyte interior antibody can also be inhibited to generate.It can reach
The purpose of similar subtotal thyroidectomy.But it is for gestation and breast feeding women and serious visceral injury and expophthalmos patient
Iodine is used in taboo131I's.In addition,131The complication such as I, which is treated, can have first to subtract, radiation thyroiditis occur.In recent years, compared to radiation
Property131I treatment and operative treatment, ATD are the most common therapeutic modalities of the therapeutic GD disease of non-hardly possible.But ATD is treated in clinical application
There are high recurrence rate, treatment cycle are long, it is unobvious to huge goiter curative effect the disadvantages of, this often brings huge warp to patient
Ji and stress.
Chinese medicine thinks that the pathomechanism of GD is a continually changing process, and initial stage shows as depression and stagnation of QI more, with the passing of time strongly fragrant
And change fire, occur that conscience stomach fire is prosperous, burning hot heresy is flourishing, and for heat evil refining liquid at phlegm, convulsive seizure due to phlegm-fire knot thyroid gland diffusivity occurs in neck
Enlargement and hyperfunction；Convulsive seizure due to phlegm-fire cohesion, it is touching refractory with the passing of time at the stasis of blood.Its hyperactivity of yang due to yin deficiency is basic pathogenesis, and characteristic of disease is to belong to this void mark
Real example, the deficiency of Yin are this, and the stagnation of the circulation of vital energy, phlegm are solidifying, blood stasis is mark.Traditional Chinese medicine is due to safe ready, easy to operate, at low cost, cure rate
The advantages that height, wide adaptability, has significant advantage when treating GD.Treatment of the traditional Chinese medicine for GD, in addition to improving symptom, also
It can reduce Western medicine side effect, therefore have been to be concerned by more and more people.Also there is the drug for treating GD in Traditional Chinese medical theory,
But Chinese medicine quantity is more, although for Chinese medicine Small side effects are only with respect to Western medicine, with the increase of traditional Chinese medicinal components, this pair
The risk of effect can also increase therewith.Therefore it provides a kind of component is few, highly-safe and can anticipate to the effective composition of GD
Justice is far-reaching.
Summary of the invention
In view of this, the purpose of the present invention is to provide a kind of for alleviating the composition and its system of hyperthyroidism
Preparation Method and application, composition components provided by the invention are simple, and it is obvious to alleviate hyperthyroidism effect.
For achieving the above object, the present invention adopts the following technical scheme:
It is a kind of for alleviating the composition of hyperthyroidism, be made of cape jasmine, Radix Paeoniae Alba, Radix Glehniae and cortex moutan.
Composition material of the present invention is medical and edible dual purpose plant.Cape jasmine is the fruit of madder wort cape jasmine.Cape jasmine
The fruit of son is traditional Chinese medicine, belongs to the 1st batch of dual-purpose of drug and food resource that the Ministry of Public Health promulgates, has protect liver, cholagogue, decompression, calmness, stops
The effects of blood, detumescence.Radix Paeoniae Alba is Ranunculaceae Chinese herbaceous peony platymiscium, has long cultivation history, has won fame both at home and abroad, also referred to as white flower Chinese herbaceous peony
Medicine, root can be used as medicine.It is recorded according to Shennong's Herbal, " bitter puts down, cures mainly perverse trend abdominal pain, removes blood-arthralgia, breaks hard long-pending, fever and chills,
Hernia lump in the abdomen, analgesic, diuresis, QI invigorating ".Contain a variety of active ingredients such as Paeoniflorin, paeonol, paeoniflorin, volatile oil in Radix Paeoniae Alba,
With pharmacological action abundant, such as antibacterial, anti-inflammatory, antipyretic-antalgic, blood pressure lowering, Liver protection, antiulcer, adjusting blood glucose.It is northern husky
Ginseng is umbelliferae glehnia littoralis, is used as medicine with root, is clinically used drugs for nourishing yin, nourishiing yin to clear away the lung-heat, expelling phlegm and arresting coughing, and it is dry to cure mainly the dryness of the lung
The diseases such as cough, consumption of body fluid caused by febrile disease, thirsty.Its nutritional ingredient rich in, such as volatile oil, cumarin, starch, alkaloid, triterpenic acid
Deng.Studies have shown that Radix Glehniae can improve T cell ratio, lymphocyte transformation rate is improved, increasing leukocyte enhances macrophage
Function extends antibody there are the time, improves B cell, promote immune function.Radix Glehniae can enhance healthy tendency, reduce disease, pre- to give protection against cancer
The generation of disease.Cortex moutan be ranunculaceae peony dry root skin, bitter, pungent, slightly cold, return heart, liver and kidney channel, have clearing heat and cooling blood,
It activates blood circulation and disperses blood clots, reducing the asthenic fever and other effects.Modern research shows that there is cortex moutan anti-inflammatory, antibacterial, anti-oxidant, antithrombotic, enhancing to exempt from
The effects of epidemic disease, blood pressure lowering.
Preferably, the composition is by weight, by 2~30 portions of cape jasmines, 2~30 portions of Radix Paeoniae Albas, 2~30 portions of Radix Glehniaes
It is made with 2~30 parts of cortex moutans；It is highly preferred that by 3~20 portions of cape jasmines, 3~20 portions of Radix Paeoniae Albas, 3~20 portions of Radix Glehniaes and 3~20 parts
Cortex moutan is made.
In the specific embodiment of the invention, the composition can be made according to following raw material:
(1) 10 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae, 10 parts of cortex moutan；
(2) 3 parts of cape jasmine, 20 parts of Radix Paeoniae Alba, 3 parts of Radix Glehniae, 20 parts of cortex moutan；
(3) 20 parts of cape jasmine, 3 parts of Radix Paeoniae Alba, 20 parts of Radix Glehniae, 3 parts of cortex moutan；
(4) 5 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 5 parts of Radix Glehniae, 10 parts of cortex moutan；
(5) 10 parts of cape jasmine, 5 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae, 5 parts of cortex moutan；
(6) 2 parts of cape jasmine, 30 parts of Radix Paeoniae Alba, 2 parts of Radix Glehniae, 30 parts of cortex moutan；
(7) 30 parts of cape jasmine, 2 parts of Radix Paeoniae Alba, 30 parts of Radix Glehniae, 2 parts of cortex moutan；
The present invention also provides the preparation methods of the composition, by cape jasmine, Radix Paeoniae Alba, Radix Glehniae and cortex moutan mixing and water adding
It extracts, collects extracting solution after filtering.
Wherein, preferably, described plus water quality is 8 times~12 times of the material quality.
In some embodiments, the quality of water is 10 times of raw material.
Preferably, the temperature of the extraction is 100 DEG C, and the time of the extraction is 1.5h-2.5h.
In some embodiments, the temperature of the extraction is 100 DEG C, time 2h.
Preferably, the number of the extraction is 2~3 times
In some embodiments, the number of the extraction is 2 times.
Further, the preparation method further includes the steps that concentration.
Preferably, the concentration is 8~12 times of concentration.
In some embodiments, the concentration is 10 times of concentration
Preferably, the preparation of composition of the present invention carries out under normal pressure.
In certain embodiments, the composition the preparation method comprises the following steps: take cape jasmine, Radix Paeoniae Alba, Radix Glehniae and cortex moutan,
The water of 10 times of quality is added, extracting solution is collected by filtration in 100 DEG C of extraction 2h；The water of 10 times of quality is added in filter residue again, and 100 DEG C mention
2h is taken, extracting solution is collected by filtration；Merge extracting solution twice, the composition is made in 10 times of concentration.
Experiment shows that composition provided by the invention is able to suppress thyroid cell and is proliferated, improvement thyroid hormone FT3,
FT4 and TSH is horizontal, alleviates Thyroid Gland Swell symptom, to have effects that alleviate hyperthyroidism and protect thyroid.
Based on above-mentioned effect, the invention proposes the composition preparation improve hyperthyroidism health care product or
Application in drug.
It wherein, in the present invention, can routinely technique and health care product or drug be respectively received by the present composition
Auxiliary material is prepared into a variety of dosage forms, such as tablet, capsule, granule, pill, mixture, powder, oral solution, soft capsule and aerosol
Deng.
According to above-mentioned application, the present invention provides a kind of for alleviating the health care product of the hyperfunction effect of thyroid gland, including described
Auxiliary material is subjected on composition and health care product.Additionally provide simultaneously it is a kind of for alleviating the drug of the hyperfunction effect of thyroid gland, including
Auxiliary material is subjected on the composition and drug.
From the above technical scheme, the cape jasmine, Radix Paeoniae Alba Radix Glehniae of the selected integration of drinking and medicinal herbs of composition of the present invention and male
The root bark of tree peony is made, and each component reasonable compatibility generates synergy synergistic effect, is able to suppress thyroid cell proliferation, improves thyroid hormone
FT3, FT4 and TSH are horizontal, alleviate Thyroid Gland Swell symptom, alleviate the hyperfunction effect of thyroid gland to play.The combination is simple,
It is highly-safe, it has no toxic side effect, quickly effective, curative effect is clear.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described.
Fig. 1 shows that groups of animals thyroid cell proliferation is horizontal, and * indicates the P < 0.05 compared with model group, has conspicuousness poor
It is different；
Fig. 2 shows the statistical chart of each group serum thyroid functional parameter, wherein figure A is the statistical chart of each group serum TSH index,
Scheme the statistical chart that B is 3 index of each group serum FT, figure C is the statistical chart of 4 index of each group serum FT, and * indicates the P compared with model group
< 0.05；
Fig. 3 shows give composition after each group thyroid gland shape size variation.
Specific embodiment
The invention discloses a kind of compositions and the preparation method and application thereof for alleviating hyperthyroidism.Ability
Field technique personnel can use for reference present disclosure, be suitably modified realization of process parameters.In particular, it should be pointed out that all similar replaces
Change and change apparent to those skilled in the art, they are considered as being included in the present invention.Side of the invention
Method and product are described by preferred embodiment, related personnel obviously can not depart from the content of present invention, spirit and
Method described herein is modified in range or appropriate changes and combinations, carrys out implementation and application the technology of the present invention.
For a further understanding of the present invention, below in conjunction with the embodiment of the present invention, to the technical side in the embodiment of the present invention
Case is clearly and completely described, it is clear that and described embodiments are only a part of the embodiments of the present invention, rather than all
Embodiment.Based on the embodiments of the present invention, those of ordinary skill in the art institute without making creative work
The every other embodiment obtained, shall fall within the protection scope of the present invention.
Unless otherwise specified, reagent involved in the embodiment of the present invention is commercial product, can pass through business canal
Road purchase obtains.
Embodiment 1, composition of the present invention
Be prepared by the medicinal material of following parts by weight for primary raw material: 10 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae,
10 parts of cortex moutan.
The preparation method comprises the following steps: taking 10 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae, 10 parts of cortex moutan, it is institute's medication that weight, which is added,
The water that 10 times of material total weight is protected boiling 2h, is extracted 2 times after boiling, merge 2 filtrates, 10 times of concentrations.
Embodiment 2, composition of the present invention
It is prepared by the medicinal material of following parts by weight for primary raw material: 3 parts of cape jasmine, 20 parts of Radix Paeoniae Alba, 3 parts of Radix Glehniae, male
20 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Embodiment 3, composition of the present invention
It is prepared by the medicinal material of following parts by weight for primary raw material: 20 parts of cape jasmine, 3 parts of Radix Paeoniae Alba, 20 parts of Radix Glehniae, male
3 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Embodiment 4, composition of the present invention
It is prepared by the medicinal material of following parts by weight for primary raw material: 5 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 5 parts of Radix Glehniae, male
10 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Embodiment 5, composition of the present invention
It is prepared by the medicinal material of following parts by weight for primary raw material: 10 parts of cape jasmine, 5 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae, male
5 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Embodiment 6, composition of the present invention
It is prepared by the medicinal material of following parts by weight for primary raw material: 2 parts of cape jasmine, 30 parts of Radix Paeoniae Alba, 2 parts of Radix Glehniae, male
30 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Embodiment 7, composition of the present invention
It is prepared by the medicinal material of following parts by weight for primary raw material: 30 parts of cape jasmine, 2 parts of Radix Paeoniae Alba, 30 parts of Radix Glehniae, male
2 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Comparative example 1,
It is prepared by the medicinal material of following parts by weight for primary raw material: 10 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae.
The preparation method is the same as that of Example 1.
Comparative example 2,
It is prepared by the medicinal material of following parts by weight for primary raw material: 10 parts of cape jasmine, 10 parts of Radix Paeoniae Alba, 10 parts of cortex moutan.
The preparation method is the same as that of Example 1.
Comparative example 3,
It is prepared by the medicinal material of following parts by weight for primary raw material: 10 parts of cape jasmine, 10 parts of Radix Glehniae, cortex moutan 10
Part.
The preparation method is the same as that of Example 1.
Comparative example 4,
It is prepared by the medicinal material of following parts by weight for primary raw material: 10 parts of Radix Paeoniae Alba, 10 parts of Radix Glehniae, cortex moutan 10
Part.
The preparation method is the same as that of Example 1.
Comparative example 5,
It is prepared by the medicinal material of following parts by weight for primary raw material: 1 part of cape jasmine, 50 parts of Radix Paeoniae Alba, 1 part of Radix Glehniae, male
50 parts of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Comparative example 6,
It is prepared by the medicinal material of following parts by weight for primary raw material: 50 parts of cape jasmine, 1 part of Radix Paeoniae Alba, 50 parts of Radix Glehniae, male
1 part of the root bark of tree peony.
The preparation method is the same as that of Example 1.
Test example 1, pharmacodynamic study
The effect of to verify composition provided by the invention, the combination for taking above-described embodiment 1~7 and comparative example 1~6 to prepare
Object carries out efficacy validation test, specific as follows:
1, test material
1.1 test specimen
Composition prepared by Examples 1 to 7 and comparative example 1~6
1.2 experimental animal
Healthy female BALB/c mouse, 6-8 week old, SPF grades
2 test methods
2.1 modelings and administration
Mouse is randomly divided into following groups: blank control group, model group, modeling+example 1 group, modeling+embodiment 2
Group, 3 groups of modeling+embodiment, 4 groups of modeling+embodiment, 5 groups of modeling+embodiment, 6 groups of modeling+embodiment, modeling+embodiment 7
Group, 1 group of modeling+comparative example, 2 groups of modeling+comparative example, 3 groups of modeling+comparative example, 4 groups of modeling+comparative example, modeling+comparative example 5
6 groups of group, modeling+comparative example.Blank control group intramuscular injection dosage is that the Ad- β-gal of 50 μ L (is diluted to 1 × 10 with PBS9pfu/
Ml), the Ad-TSHR-289 that other each groups give 50 μ L (is diluted to 1 × 10 with PBS9pfu/ml).The equal quadriceps muscle of thigh note of each group
Penetrate, every mouse immune 3 times, each immunization interval 3 weeks.
It is administered and intervenes the 6th week after since the modeling, administration group gives 3.33 μ l/g/d dosage gastric infusions, blank
Group and model group give the distilled water of equivalent, the equal successive administration of each group 28 days.
2.2 thyroid cells proliferation is horizontal
Immunohistochemical Method detects the expression of Ki-67, selects 20 high power fields at random, counts 400 first shapes in each visual field
It is horizontal to compare thyroid cell proliferation for Ki-67 positive cell number in gland cell.Calculation formula is as follows:
Thyroid cell is proliferated level=thyroid gland Ki-67 positive cell number/thyroid cell number × 100%
The detection of 2.3 serum thyroid functional parameters
After mouse takes blood, separation serum, radioimmunoassay kitss detection free serum trilute (FT3),
The level of serum free thyroxine (FT4), thyrotropic hormone (TSH).
2.4 thyroid size
Mouse thyroid diameter is measured after taking out Mouse thyroid, observes the variation of Mouse thyroid actual size.
3 test results
3.1 thyroid cells proliferation is horizontal
During Recent study shows hyperthyroidism disease, thyroid cell hyperplasia causes Thyroid Gland Swell, function
Imbalance.Experimental result discovery, compared to the blank group, it is horizontal that model group significantly increases thyroid cell proliferation.Compared with model group,
The proliferation that each group extract (Examples 1 to 7, comparative example 1~6) can all reduce thyroid cell to a certain extent is horizontal, but each
The effect of comparative example 1~6 is not significant, is substantially less than each embodiment to the protective effect of thyroid function.And Examples 1 to 7
In, the effect of embodiment 1 is best (p < 0.05), the inhibiting effect (figure horizontal better than 2~7 pairs of thyroid cell proliferation of embodiment
1)。
The detection of 3.2 serum thyroid functional parameters
It has proven convenient that FT3, FT4 that hyperthyroidism will lead to rat are increased, TSH is reduced research report.Experimental result
It has been shown that, compared with blank control group, the horizontal significant raising of FT3, FT4 of model group, TSH level is significantly reduced.Examples 1 to 7
FT3, the FT4 that can significantly reduce hyperthyroidism mouse model are horizontal, and it is horizontal to increase TSH.Comparative example 1~6 to a certain extent can also be with
It is horizontal to reduce FT3, FT4, it is horizontal to increase TSH, but act on unobvious (Fig. 2).
3.3 thyroid size
According to the thyroid gland diameter of actual measurement each group, model group thyroid gland diameter is noticeably greater than blank group (p < 0.05)；
Compared with model group, thyroid gland diameter is substantially reduced (p < 0.05) (Fig. 3) in embodiment 1.
The result of embodiment 2~7 is similar to Example 1.
The above is only the preferred embodiment of the present invention, it is noted that those skilled in the art are come
It says, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should be regarded as
Protection scope of the present invention.
Claims (10)
1. a kind of composition, which is characterized in that by weight, by 2~30 portions of cape jasmines, 2~30 portions of Radix Paeoniae Albas, 2~30 parts of north are husky
Ginseng and 2~30 parts of cortex moutans are made.
2. composition according to claim 1, which is characterized in that by weight, by 3~20 portions of cape jasmines, 3~20 parts white
Chinese herbaceous peony, 3~20 portions of Radix Glehniaes and 3~20 parts of cortex moutans are made.
3. composition according to claim 2, which is characterized in that by weight, by 5~10 portions of cape jasmines, 5~10 parts white
Chinese herbaceous peony, 5~10 portions of Radix Glehniaes and 5~10 parts of cortex moutans are made.
4. the preparation method of composition described in claims 1 to 3 any one, which is characterized in that by cape jasmine, Radix Paeoniae Alba, Radix Glehniae
It mixes with cortex moutan and is extracted through water, collect extracting solution and be made.
5. the preparation method according to claim 4, which is characterized in that further include the step that the extracting solution of collection is concentrated
Suddenly.
6. preparation method according to claim 5, which is characterized in that with 8~12 times of water of the composition gross mass,
100 DEG C of extraction 1.5h~2.5h, gained extracting solution obtain the composition after being concentrated 8~12 times.
7. according to claim 1~3 composition described in any one preparation improve hyperthyroidism in health care product and/or
Application in drug.
8. applying according to claim 7, which is characterized in that the dosage form of the health care product or drug is solid pharmaceutical preparation or liquid
Body preparation；
The solid pharmaceutical preparation is tablet, capsule, granule, pill, pill, mixture or powder；
The liquid preparation is oral solutions, soft capsule, aerosol.
9. a kind of for alleviating the health care product of hyperthyroidism, which is characterized in that include group described in right 1-3 any one
It closes and is subjected to auxiliary material on object and health care product.
10. a kind of for alleviating the drug of hyperthyroidism, which is characterized in that include group described in right 1-3 any one
It closes and is subjected to auxiliary material on object and drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810298854.0A CN110314183A (en) | 2018-03-30 | 2018-03-30 | A kind of composition and the preparation method and application thereof for alleviating hyperthyroidism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810298854.0A CN110314183A (en) | 2018-03-30 | 2018-03-30 | A kind of composition and the preparation method and application thereof for alleviating hyperthyroidism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110314183A true CN110314183A (en) | 2019-10-11 |
Family
ID=68112518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810298854.0A Pending CN110314183A (en) | 2018-03-30 | 2018-03-30 | A kind of composition and the preparation method and application thereof for alleviating hyperthyroidism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110314183A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528427A (en) * | 2003-10-17 | 2004-09-15 | 江西山香药业有限公司 | Chinese medicine for treating hyperthyroidism |
| CN102895407A (en) * | 2012-11-08 | 2013-01-30 | 徐飞 | Chinese herbal medicine composition for treating hyperthyroidism and method for preparing Chinese herbal medicine composition for treating hyperthyroidism |
-
2018
- 2018-03-30 CN CN201810298854.0A patent/CN110314183A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1528427A (en) * | 2003-10-17 | 2004-09-15 | 江西山香药业有限公司 | Chinese medicine for treating hyperthyroidism |
| CN102895407A (en) * | 2012-11-08 | 2013-01-30 | 徐飞 | Chinese herbal medicine composition for treating hyperthyroidism and method for preparing Chinese herbal medicine composition for treating hyperthyroidism |
Non-Patent Citations (1)
| Title |
|---|
| 李苏珊等: "王旭教授从肝脾肾分期论治甲亢突眼的经验 ", 《浙江中医药大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101559092B (en) | Application of eucommia ulmoides extracts | |
| CN102764339B (en) | Maca composition for improving sexual dysfunction and preparation method and application thereof | |
| CN103621869B (en) | Giant salamander oligosaccharide peptide health-care product | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| CN103585479A (en) | Blood-replenishing pill and blood-replenishing capsule for treating iron-deficiency anemia | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN105497261A (en) | Matrix of patch for external use and patch and sleeping-aid patch made from matrix | |
| CN101214289A (en) | Chinese medicinal composition for treating thrombocytopenic purpura and preparation thereof | |
| CN105943651A (en) | Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof | |
| CN102423335A (en) | Medicine combination for treating impotence and premature ejaculation and preparation method thereof | |
| CN103610795A (en) | Method for preparing eucommia ulmoides step-down oral preparation | |
| CN101023979A (en) | Lamiophlomis-rotata leaf-stem distract and its preparing process and use | |
| CN110313616A (en) | It is a kind of to have effects that alleviate the hyperfunction composition and the preparation method and application thereof of thyroid gland | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN110314183A (en) | A kind of composition and the preparation method and application thereof for alleviating hyperthyroidism | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN1517115A (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN102293923A (en) | Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN101554397B (en) | Applications of eucommia ulmoide total alkaloid | |
| CN105194352A (en) | Traditional Chinese medicine composition capable of improving learning and memory abilities and preparation method thereof | |
| CN104258276A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191011 |
|
| RJ01 | Rejection of invention patent application after publication |